Gabapentin: Independent Evidence on Pain, Epilepsy & Misuse Risk
Gabapentin (Neurontin): what independent reviews show for nerve pain and epilepsy, why off-label use outran the evidence, opioid and breathing risks, and who funded it.
Independent research on stress, anxiety and depression — supplement and lifestyle claims graded honestly, with funding and conflicts made transparent.
Gabapentin (Neurontin): what independent reviews show for nerve pain and epilepsy, why off-label use outran the evidence, opioid and breathing risks, and who funded it.
Independent review of lamotrigine for epilepsy and bipolar maintenance: SANAD, Cochrane evidence, serious rash, pregnancy, the pill, the 2021 FDA warning and funding.
Baricitinib and ritlecitinib regrow hair in severe alopecia areata while taken, but hair is usually lost after stopping; most other options have weak evidence.
Independent evidence on vitiligo treatments, phototherapy and ruxolitinib cream, plus the funding behind the trials and supplement claims.
Creams such as ivermectin and azelaic acid have the best independent support for rosacea bumps, and brimonidine for redness, but most key trials were company-run.
Most chronic cough has a treatable cause. For unexplained cough, gabapentin and speech therapy rest on small trials, and gefapixant helps modestly in maker-sponsored trials.
Small trials suggest curcumin may slightly ease depression, mostly with antidepressants, but many were maker-linked and concentrated supplements carry a rare liver risk.
Depression risk rises in perimenopause. We review NICE advice, HRT and CBT trials, antidepressants and new hot-flush drugs, and who funds the evidence.
Self-harm is common and linked to later suicide. Talking therapies such as DBT for teenagers have the best evidence; no medicine or risk score is proven to help.
Stress shedding (telogen effluvium) usually regrows on its own. Independent evidence on causes to rule out, minoxidil, biotin risks and who funds hair-supplement trials.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.